Biotherapeutics Antibody for the Treatment of Solid Cancers

BioTherapeutics is focused on developing innovative antibody-based cancer treatments, based on a range of proprietary technologies. These target a number of oncology indications, with a particular focus on cancers with limited treatment options. These include a mixture of solid and liquid malignancies, such as acute myeloid leukemia and breast, ovarian and lung cancers. Monoclonal antibodies have emerged as a class of novel oncology therapeutics. 

The selectivity and specificity, the unique pharmacokinetics, and the ability to engage and activate the immune system differentiate these biologics from traditional small molecule anticancer drugs.

  • Advances in bispecific biotherapeutics for the treatment of cancer
  • Antibody-drug conjugates for cancer therapy
  • Angiogenesis inhibitor antibodies
  • Biotherapeutic approaches to target cancer stem cells

Related Conference of Biotherapeutics Antibody for the Treatment of Solid Cancers

November 2-3, 2017

9th World Congress and Expo on Immunology

Atlanta, Georgia, USA
November 02-03, 2017

9th World Congress on Immunity, Inflammation and Immunotherapies

Atlanta, Georgia, USA
November 06-07, 2017

2nd International Conference on Autoimmunity

Frankfurt, Germany
November 08-09, 2017

3rd Antibodies and Bio Therapeutics Congress & B2B

Las Vegas, Nevada, USA
November 13-14, 2017

5th International Conference on HIV/AIDS, STDs and STIs

Las Vegas, Nevada, USA
Dec 14-15, 2017

World Immunology Congress

Dubai, UAE
April 19-20, 2018

7th World Congress on Immunology

Amsterdam, Netherlands
May 28-29, 2018

World Congress on Allergy and Immunotherapy

Osaka, Japan

9th European Immunology Conference

June 14-16, 2018 Rome, Italy
July 05-07, 2018

EuroSciCon Conference on Immunology Conference 2018

Vienna, Austria
July 12-13, 2018

5th International Conference on Parasitology

Paris, France

Biotherapeutics Antibody for the Treatment of Solid Cancers Conference Speakers

Recommended Sessions

Related Journals

Are you interested in